19:51 , Dec 21, 2018 |  BC Week In Review  |  Financial News

Medicxi leads Morphogen-IX’s £18.4M series B

Morphogen-IX Ltd. (Babraham, U.K.) raised £18.4 million ($23.2 million) on Dec. 18 in a series B round led by Medicxi with participation from Cambridge Innovation Capital and Cambridge Enterprise. The company will use the financing...
22:57 , Dec 18, 2018 |  BC Extra  |  Financial News

Medicxi leads Morphogen-IX’s £18.4M series B

Morphogen-IX Ltd. (Babraham, U.K.) raised £18.4 million ($23.2 million) in a series B round led by Medicxi with participation from Cambridge Innovation Capital and Cambridge Enterprise. The company will use the financing to begin "formal"...
20:15 , May 25, 2017 |  BC Innovations  |  Finance

Europe’s translational springtime

European science is showing early signs of translational growth, with VCs increasingly shifting their focus to preclinical assets. But investors are concerned the region still doesn’t have the supply of management talent or funding it...
07:00 , Jul 9, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Bone morphogenetic protein 9 (BMP9; GDF2); bone morphogenetic protein receptor type II (BMPRII)

Cardiovascular disease INDICATION: Hypertension Cell culture and mouse studies suggest BMP9 could help treat pulmonary arterial hypertension (PAH). Mutations in BMPRII have been associated with PAH pathogenesis. In assays in endothelial cells from PAH patients...
08:00 , Jan 9, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Bone morphogenetic protein 9 (BMP9; GDF2) Mouse studies suggest BMP9 could be useful for treating AD. In a mouse model of AD,...